Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy

Kennedy's Disease Clinical Trial

Official title:
Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy in Thai Patients

Status Completed

Clinical Trial Summary

This is a therapeutic trial study to demonstrate whether Goserelin, a LHRH agonist has benefit in SBMA

Objective:

1. To study effects of Goserelin to clinical course of patients with spinal and bulbar muscular atrophy in Thailand

2. To demonstrate physiological and pathological changes in treated patients with Goserelin.

3. To assess tolerability and adverse effect of Goserelin therapy

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00851461
Study type	Interventional
Source	Ramathibodi Hospital
Contact
Status	Completed
Phase	Phase 4
Start date	April 2008
Completion date	November 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00303446` - Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA)	Phase 2
Completed	`NCT03560661` - Acoustic and Perceptual Markers of Dysarthria in Amyotrophic Lateral Sclerosis (ALS)
Active, not recruiting	`NCT05517603` - A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients	Phase 1/Phase 2